Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

Researchers say the study indicates the ability to bring the power of AI and patient-reported outcomes directly into the clinic seamlessly, affordably, and at scale.

Pfizer has won the week-long bidding war for Metsera with an upwardly revised up-to-$10 billion offer matching that of rival Novo Nordisk—and more than a little help from Washington.

In this eBook, we focus on both considerations for resins, a major operating cost for a vast majority of protein therapeutics, and filtration through a series of articles.

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Engineered human stomach organoids, transplanted into mice, produced insulin-secreting cells, offering a potential new ...

In this GEN webinar, experts from Sampled and Rady Children’s Hospital will discuss the validation and clinical integration ...

The team used the AMG1541 LNP to deliver an mRNA influenza vaccine in mice. They compared this vaccine’s effectiveness to a flu vaccine made with the lipid SM-102, which is FDA-approved and was used ...

Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...

The company's initial target is immuno-oncology projects but there are plans to expand into autoimmune disease, infectious disease, and more.

Maternal type 1 diabetes is associated with specific epigenetic marks in the form of DNA methylation in children.

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.